指南与共识垂体与肾上腺疾病

原发性醛固酮增多症药物治疗后的结局:国际共识及国际队列治疗反应分析

Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort.
指南 / 共识 · Lancet Diabetes Endocrinol · 2025-01-14

国际专家组采用德尔菲法制定原发性醛固酮增多症药物治疗完全、部分或无生化及临床结局的定义,并在28个中心1258例患者中分析结局。结果显示84.0%有生化结局数据者中52.9%达完全生化缓解,18.3%达完全临床缓解,女性、基线降压药剂量较低及无微量白蛋白尿或左心室肥厚与完全临床缓解相关。

要点

  • PAMO标准由31位国际专家通过德尔菲法共识制定,用于评估原发性醛固酮增多症药物治疗结局。
  • 1258例患者中,1057例有生化结局数据,559例(52.9%)达完全生化缓解。
  • 1248例有临床结局数据者中,228例(18.3%)达完全临床缓解,227例(18.2%)为无缓解。

核心结论

  • PAMO标准是国际制定的结局评估标准,可指导原发性醛固酮增多症的临床实践和研究。
  • 需要努力优化治疗强度并减少与治疗无反应相关的因素,以改善患者结局。

研究设计与样本

  • 国际专家组31位原发性醛固酮增多症专家采用德尔菲法达成共识,定义药物治疗的完全、部分或无生化及临床结局。
  • 收集2016年至2021年在28个参与中心开始靶向药物治疗的原发性醛固酮增多症患者基线和治疗后6-12个月的临床数据。

主要发现

  • 1258例患者平均年龄52岁(SD 11.5),其中女性610例(48.5%),男性648例(51.5%)。
  • 1057例(84.0%)有生化结局数据,其中559例(52.9%)达完全生化缓解。
  • 完全生化缓解者螺内酯中位日剂量显著高于无完全生化缓解者(40 mg [IQR 25-50] vs 25 mg [20-50];p=0.011)。
  • 1248例有临床结局数据者中,228例(18.3%)达完全临床缓解,227例(18.2%)为无缓解。
  • 完全临床缓解者较部分或无临床缓解者更可能为女性(OR 2.099,95% CI 1.485-2.968;p<0.001),基线降压药剂量需求较低(0.687,0.603-0.782;p<0.001),且较少有微量白蛋白尿或左心室肥厚(0.584,0.391-0.873;p=0.009)。

关键数值与推荐

  • 共识达成了完全、部分或无生化或临床反应的定义。
  • 完全生化缓解者螺内酯中位日剂量为40 mg(IQR 25-50),无完全生化缓解者为25 mg(IQR 20-50),组间差异p=0.011。
  • 完全临床缓解与女性相关(OR 2.099,95% CI 1.485-2.968;p<0.001)。
  • 完全临床缓解与基线降压药剂量较低相关(OR 0.687,95% CI 0.603-0.782;p<0.001)。
  • 完全临床缓解与较少微量白蛋白尿或左心室肥厚相关(OR 0.584,95% CI 0.391-0.873;p=0.009)。

临床怎么用

  • PAMO标准可作为国际制定的结局标准,指导原发性醛固酮增多症的临床实践和研究。
  • 需要努力优化治疗强度并减少与治疗无反应相关的因素,以改善患者结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary aldosteronism can be treated medically but there is no standardised method to evaluate treatment outcomes. We aimed to develop criteria for assessing the outcomes of targeted medical treatment of primary aldosteronism, analyse outcomes across an international cohort, and identify factors associated with a complete treatment response. METHODS: An international panel of 31 primary aldosteronism experts used the Delphi method to reach consensus on the definition of complete, partial, or absent biochemical and clinical outcomes of medical treatment of primary aldosteronism. Clinical data at baseline and 6-12 months post-treatment were collected from patients with primary aldosteronism who started targeted medical treatment between 2016 and 2021 at 28 participating centres. FINDINGS: Consensus was reached for defining complete, partial, or absent biochemical or clinical response. Of 1258 patients (with a mean age of 52 years [SD 11·5] and of whom 610 [48·5%] were female and 648 [51·5%] were male), 1057 (84·0%) had biochemical outcome data (559 [52·9%] had a complete biochemical response). The median daily dose of spironolactone was significantly higher for those with a complete biochemical response than for those without (40 mg [IQR 25-50] vs 25 mg [20-50]; p=0·011). Of the 1248 patients with clinical outcome data, 228 [18·3%] had a complete clinical response whereas 227 (18·2%) had an absent response. Patients with a complete clinical response were more likely than those with partial or absent clinical response to be women (OR 2·099, 95% CI 1·485-2·968; p<0·001), require lower doses of antihypertensive drugs at baseline (0·687, 0·603-0·782; p<0·001), and were less likely to have microalbuminuria or left ventricular hypertrophy (0·584, 0·391-0·873; p=0·009). INTERPRETATION: The Primary Aldosteronism Medical Treatment Outcome (PAMO) criteria represent an internationally developed outcome standard that can guide clinical practice and research into primary aldosteronism. Efforts to optimise treatment intensity and minimise factors associated with an absent treatment response are needed to improve patient outcomes. FUNDING: None. TRANSLATIONS: For the Chinese (simple), Chinese (complex), Japanese, Korean, German, French, Spanish, Dutch, Swedish, Slovenian, Polish, Italian and Russian translations of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Yang J, Burrello J, Goi J, et al. Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort. Lancet Diabetes Endocrinol. 2025. PMID: 39824204. doi:10.1016/S2213-8587(24)00308-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。